Creso Pharma (ASX:CPH) - Non-Executive Director, Adam Blumenthal
Source: Adam Blumenthal/Twitter
Market Herald logo


Be the first with the news that moves the market
  • Creso Pharma (CPH) is looking to land on another US exchange after terminating its proposed merger with Red Light Holland
  • Creso says the merger is no longer in shareholder’s best interests and would be forgoing its planned listing on the Canadian Securities Exchange
  • The CSE listing was set to take place as part of its merger with Red Light Holland, which was announced in June
  • The company says the move will grant it access to “the world’s largest recreational cannabis market”
  • Creso Pharma shares are up 12.5 per cent at 3:52 pm AEST to trade at 13.5 cents

Creso Pharma (CPH) is looking to land on another US exchange after terminating its proposed merger with Red Light Holland.

Creso said the companies concluded the merger would “no longer be in the best interests of their respective shareholders” and that Creso would instead shift its focus towards a proposed NASDAQ dual listing.

The move reportedly follows extensive due diligence from Creso, which resulted in the decision that pending regulatory changes in North America would provide “ample opportunities” in the near term.

The move undoes CPH’s arrangement with the Canadian “magic truffle business” Red Light Holland, under which CPH would have had to delist from the ASX and list on the Canadian Securities Exchange under the ticker code TRIP.

In rationale for the move, non-executive Chairman Mr Adam Blumenthal said the listing could allow for easier comparisons to North American listed peers.

“Following potentially favourable legislative shifts, a NASDAQ listing will also provide us with access to the world’s largest recreational cannabis market and
a growing psychedelic medicines sector,” he said.

“Pleasingly, a dual listing opportunity will also allow Creso Pharma to retain its ASX listing, which we believe is in the best interests of our longstanding and faithful shareholders.”

Creso Pharma is also listed on the US OTCQB stock exchange.

Creso has appointed New York-based corporate advisory firm, EAS Advisors to aid with the proposed listing.

Red Light Holland has placed an order to purchase $170,000 of Creso Pharma’s hemp-based CBD products, with Creso reaffirming the companies remain committed to a strong working relationship.

Creso Pharma shares were up 12.5 per cent at 3:52 pm AEST to trade at 13.5 cents.

CPH by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
The Market Herald Video

" Vulcan Energy (ASX:VUL) in trading halt after shock short seller report

Vulcan Energy (VUL) remains in a trading halt as it deals with accusations from short-seller J Capital Research that it misled investors.
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.